Healthspan, Not Lifespan: What Longevity Science Can Measure Today and What It Only Promises

Longevity is often sold as a promise to reach 120. Aging researchers talk about something else: lifespan, the total years lived, matters less than healthspan, the period when a person is independent, mobile and not dependent on treating chronic disease. The gap is easy to see. Someone can live to 85 and spend the last fifteen years with heart failure or dementia.

The concept itself is not new. What is new is the attempt to turn healthspan into something measurable. That is what this section of FUTURMAG is about: not “sleep more” advice, but technologies that make healthy aging testable.

Why measurement is the real problem

Healthspan has no single definition. Some define it as time before the first serious chronic disease, others as time before loss of independence, others through quality-of-life scales. That makes studies hard to compare and interventions hard to evaluate.

There is also a regulatory side. Regulators, including the FDA, do not recognize aging as an indication: a drug has to be approved for a specific disease. Trials of geroprotective drugs therefore rely on proxies such as diabetes, cardiovascular events or functional tests. The TAME trial of metformin was conceived to test that approach itself, to see whether a cluster of age-related diseases can work as an endpoint. Check its current status on the project’s official pages rather than in headlines.

Four tiers of tools

It helps to sort what the market offers by maturity.

1. Validated risk markers. Blood pressure, ApoB or non-HDL cholesterol, HbA1c, waist circumference, coronary artery calcium score. This layer is dull but the most reliable: decades of data link these numbers to outcomes.

2. Functional tests. Grip strength, walking speed, repeated chair stands, maximal oxygen uptake (VO₂max). They predict risk and independence well and cost almost nothing. We cover how watches digitize one of them in the VO₂max article .

3. Wearables. Rings and watches provide continuous data: resting heart rate, heart rate variability, sleep, activity. They are good for tracking one person’s trend and poor at absolute values; see the comparison of rings, straps and watches .

4. Omics and “aging clocks”. Epigenetic clocks, proteomic panels, metabolomics. This is the most exciting and most contested tier: the tools measure statistical patterns, not diagnoses. How to read such results is explained in our piece on third-generation epigenetic clocks .

What about interventions

In animal experiments several compounds extend lifespan; the best evidence is for rapamycin in the US National Institute on Aging’s Interventions Testing Program. In humans the picture is more modest: safety and effects on individual markers are being studied, but extension of healthy life has not been shown. More in our piece on supplements and senolytics .

The practical takeaway is that lifestyle changes remain the intervention with the strongest evidence, while technology helps you see where you stand and whether your chosen path is working.

How we rate technologies in the Human section

For every topic we state the stage: lab research, human trials, clinical use or consumer product. We separate “associated with risk” from “reduces risk”. We do not promise that a test or supplement will extend life, and we flag when a decision belongs with a doctor.